Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Reata Pharmaceuticals (RETA) stocks
Learn how to easily invest in Reata Pharmaceuticals stocks.
Reata Pharmaceuticals is a biotechnology business based in the US. Reata Pharmaceuticals stocks (RETA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $139.36 – an increase of 0.95% over the previous week. Reata Pharmaceuticals employs 346 staff and has a trailing 12-month revenue of around $10 million.
How to buy stocks in Reata Pharmaceuticals
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RETA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Reata Pharmaceuticals?
- Has coronavirus impacted Reata Pharmaceuticals shares?
- Reata Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Reata Pharmaceuticals stock a buy or sell?
- Reata Pharmaceuticals performance over time
- Reata Pharmaceuticals's financials
- How volatile are Reata Pharmaceuticals shares?
- Does Reata Pharmaceuticals pay a dividend?
- Other common questions
Reata Pharmaceuticals stock price (NASDAQ:RETA)Use our graph to track the performance of RETA stocks over time.
Reata Pharmaceuticals shares at a glance
|Latest market close||$25.52|
|52-week range||$18.47 - $114.80|
|50-day moving average||$25.76|
|200-day moving average||$28.98|
|Wall St. target price||$50.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-8.35|
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Reata Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Reata Pharmaceuticals price performance over time
|1 week (2022-09-28)||0.95%|
|1 month (2022-09-01)||0.12%|
|3 months (2022-07-05)||-30.06%|
|6 months (2022-04-05)||-28.87%|
|1 year (2021-10-05)||-74.16%|
|2 years (2020-10-05)||-75.98%|
|3 years (2019-10-04)||80.24|
|5 years (2017-10-05)||31.39|
Reata Pharmaceuticals financials
|Revenue TTM||$10 million|
|Gross profit TTM||$-144,503,000|
|Return on assets TTM||-22.86%|
|Return on equity TTM||-159.3%|
|Market capitalisation||$936.1 million|
TTM: trailing 12 months
Reata Pharmaceuticals share dividends
We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.
Reata Pharmaceuticals share price volatility
Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $18.47 up to $114.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.155. This would suggest that Reata Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Reata Pharmaceuticals overview
Reata Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co. , Ltd.
Stocks similar to Reata Pharmaceuticals
Reata Pharmaceuticals in the news
Reata Pharma (RETA) is Striving Hard Despite Pipeline Setbacks
Moore Kuehn, PLLC Encourages Investors of Reata Pharmaceuticals, Inc. to Contact Law Firm
Positive week for Reata Pharmaceuticals, Inc. (NASDAQ:RETA) institutional investors who lost 76% over the past year
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
A simple guide to buying stocks in your favourite European soccer team.Read more…
Rethink how you grow your money with these green investment strategies and key green stocks.Read more…
Using our proprietary algorithm, we searched the TSX, NYSE and Nasdaq to find the 10 best penny stocks to buy now.Read more…
More guides on Finder
How to buy NFI Group stock in Canada
Steps to owning and managing NFI stock, with 24-hour and historical pricing before you buy.
How to buy Laser Photonics Corp (LASE) stock in Canada when it goes public
Everything we know about the Laser Photonics Corp IPO plus information on how to buy in.
How to buy YanGuFang International Group (YGF) stock in Canada when it goes public
Everything we know about the YanGuFang International Group IPO plus information on how to buy in.
How to buy ParaZero Technologies (PRZO) stock in Canada when it goes public
Everything we know about the ParaZero Technologies IPO plus information on how to buy in.
How to buy Li Bang International Corporation (LBGJ) stock in Canada when it goes public
Everything we know about the Li Bang International Corporation IPO plus information on how to buy in.
How to buy Boustead Wavefront (BOUW) stock in Canada when it goes public
Everything we know about the Boustead Wavefront IPO plus information on how to buy in.
How to buy NYIAX (NYX) stock in Canada when it goes public
Everything we know about the NYIAX IPO plus information on how to buy in.
How to buy Adamas One Corp (JEWL) stock in Canada when it goes public
Everything we know about the Adamas One Corp IPO plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock in Canada when it goes public
Everything we know about the BIOLIFE4D IPO plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.